Collagenase clostridium histolyticum OK in Peyronie's

Collagenase clostridium histolyticum OK in peyronie's
For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal of Urology.

(HealthDay)—For patients with Peyronie's disease, treatment with collagenase clostridium histolyticum (CCH) intralesional injections is efficacious and tolerable, according to research published online Feb. 1 in The Journal of Urology.

Martin Gelbard, M.D., from the Urology Associates Medical Group in Burbank, Calif., and colleagues examined the clinical efficacy and safety of CCH intralesional injections among patients with Peyronie's disease (417 and 415 patients in Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies [IMPRESS] I and II, respectively). CCH injections were given through a maximum of four treatment cycles, each separated by six weeks, with two injections per cycle.

Based on meta-analysis of data from the two studies, the researchers found that patients treated with CCH experienced a mean 34 percent improvement in penile curvature deformity, compared with a mean 18.2 percent improvement seen in placebo-treated individuals (P < 0.0001). In CCH-treated versus -treated individuals, the mean change in Peyronie's disease bother score was significantly improved. There were three corporal rupture serious adverse events, all of which were repaired surgically.

"The IMPRESS I and II studies support the clinical efficacy and safety of CCH treatment for both the physical and psychological aspects of Peyronie's disease," the authors write.

Several authors disclosed financial ties to Auxilium Pharmaceuticals, which funded the study and manufactures and markets CCH.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Latrepirdine not effective in Huntington's disease

Nov 01, 2012

(HealthDay)—Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease ...

R.E.N.A.L. nephrometry score predicts treatment efficacy

Dec 27, 2012

(HealthDay)—The R.E.N.A.L. (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior and location relative to polar lines) nephrometry scoring system predicts the efficacy ...

Long-term ranibizumab beneficial for macular edema

Oct 11, 2012

(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity ...

Adalimumab relieves hidradenitis suppurativa

Dec 18, 2012

(HealthDay)—For patients with moderate-to-severe hidradenitis suppurativa (HS), a chronic skin disease characterized by painful abscesses, nodules, and draining fistulas in the axilla and groin, treatment ...

Recommended for you

Cooling of dialysis fluids protects against brain damage

10 hours ago

While dialysis can cause blood pressure changes that damage the brain, cooling dialysis fluids can protect against such effects. The findings come from a study appearing in an upcoming issue of the Journal of the American So ...

Two Ebola vaccines to be tested in Switzerland

11 hours ago

Clinical trials of two experimental vaccines against the deadly Ebola virus are due to begin soon in Switzerland, the country's Tropical and Public Health Institute said on Thursday.

Legionnaire's disease kills four in Spain

15 hours ago

Four people have died from an outbreak of the lung infection Legionnaire's disease in northeastern Spain, regional health authorities said Thursday.

User comments